Mr. Michael Frank reports

REVIVE THERAPEUTICS REPORTS GRANT OF OPTIONS

Revive Therapeutics Ltd.'s board of directors has authorized the grant of an aggregate of 15.5 million incentive stock options to key members of the company's team, including directors, officers and consultants. The stock options have an exercise price of five cents per share for a period of five years. All options were granted pursuant to the company's 10-per-cent rolling stock option plan and are subject to the terms of the plan, the applicable grant agreement and the requirements of the Canadian Securities Exchange. These stock options are an essential component of the company's strategy to drive performance and incentivize excellence as Revive advances its corporate objectives.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness.